Evidence map›Paper›PMID 40792170›Full record

ArticleTranslational cancer research2025

Downregulation of

Hyung-Joon Yoon, Eun Taeg Kim, Changho Song

Abstract read
In one paragraph

Article in Translational cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Hyung-Joon YoonDepartment of Obstetrics and Gynecology, Pusan National University School of Medicine, Busan, Republic of Korea.ORCID https://orcid.org/0000-0002-9154-4884
Eun Taeg KimDepartment of Obstetrics and Gynecology, Kosin University College of Medicine, Busan, Republic of Korea.
Changho SongDepartment of Obstetrics and Gynecology, Ulsan University College of Medicine, Ulsan University Hospital, Ulsan, Republic of Korea.ORCID https://orcid.org/0000-0001-5530-6419

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Cervical cancer (CC) is the fourth most common cancer in women. Prognostic biomarkers for CC, particularly squamous cell carcinoma (SCC), are limited despite their clinical significance. ANKRD22, an ankyrin repeat domain protein, has been implicated in several cancers, but its role in CC remains unclear. In this study, we aimed to analyze the relationship between Methods: Gene expression profiles were obtained from GEO datasets (GSE63514, GSE6791), and RNA sequencing and clinical data were obtained from The Cancer Genome Atlas. Clinical characteristics included age, Federation of Gynecology and Obstetrics 2009 stage, histological grade, lympho-vascular space invasion, and treatment response. Patients were stratified by Results: Conclusions:

Indexed as

ANKRD22bioinformaticsCervical cancer (CC)prognosissquamous cell carcinoma (SCC)

Identifiers

PMID40792170
PMCPMC12335679

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.